Condition: MF · Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd
This trial adopts a multicenter, open label, positive drug parallel controlled clinical trial design, with a planned enrollment of approximately 105 participants in the MF trial. Successful trial participants were selected and assigned to either the experimental group or the control group in a 2:1 stratified manner, with the stratification factor being the Dynamic International Prognostic Scoring System (DIPSS) prognostic grading criteria. Continuously take the test drug/control drug until it meets the withdrawal criteria.
This description comes directly from the study's public registry record.
Wang Fangmei · 13808086495 · fangmei.wang@zenitar.cn
Sun Liangkun · 15885742617 · liangkunsun@zenitar.cn
Always discuss trial participation with your own doctor first.
| West China Hospital Sichuan University | Chengdu, Sichuan, China | Recruiting |
| Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (IHCAMS) | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07317700